BioXcel Therapeutics (BTAI) Cash & Equivalents (2017 - 2026)

BioXcel Therapeutics' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $17.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 44.6% year-over-year to $17.2 million in Q1 2026; TTM through Mar 2026 was $17.2 million, a 44.6% decrease from a year earlier, with the FY2025 full-year figure at $28.4 million, down 4.82% from the prior year.
• Cash & Equivalents eased to $17.2 million in Q1 2026 per BTAI's latest filing, from $28.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $233.5 million in Q2 2022 and bottomed at $17.2 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $65.2 million (2023), against an average of $96.4 million.
• Across the five-year window, Cash & Equivalents gained 3.31% in 2022 and tumbled 69.02% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $193.7 million in 2022, then tumbled by 66.33% to $65.2 million in 2023, then plunged by 54.23% to $29.9 million in 2024, then decreased by 4.82% to $28.4 million in 2025, then plunged by 39.54% to $17.2 million in 2026.
• Per Business Quant, the three latest BTAI Cash & Equivalents figures stand at $17.2 million (Q1 2026), $28.4 million (Q4 2025), and $36.2 million (Q3 2025).